Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, multi-center, two-part, randomized, placebo-controlled study of the safety, tolerability, and efficacy of 4 weeks of treatment with AP1189 in early rheumatoid arthritis (RA) patients with active joint disease

Next Previous
Trial Profile

A double-blind, multi-center, two-part, randomized, placebo-controlled study of the safety, tolerability, and efficacy of 4 weeks of treatment with AP1189 in early rheumatoid arthritis (RA) patients with active joint disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Resomelagon (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms BEGIN; SynAct-CS002
  • Sponsors Synact Pharma

Most Recent Events

  • 14 Nov 2022 Primary endpoint (Change in CDAI), has been met, as per results presented at the ACR Convergence 2022.
  • 14 Nov 2022 Results assessing the safety, tolerability and efficacy of AP1189 in early rheumatoid arthritis patients with active joint disease, presented at the ACR Convergence 2022.
  • 26 Nov 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top